Sign In
Buy MRSN
$29.08
+0 (+0%)
At Close: Apr 02, 2026
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Mersana Therapeutics Starts UpRi Dosing In Heavily Pretreated Cohort Of Ovarian Cancer Patients
10:17am, Friday, 09'th Apr 2021
Mersana Therapeutics Inc (NASDAQ: MRSN) has initiated patient dosing in the UPLIFT study evaluating upifitamab rilsodotin in patients with ovarian cancer. The single-arm registration strategy will
Conference Call and webcast to be held on Friday, April 16, 2021, at 8:00 a.m. ET Conference Call and webcast to be held on Friday, April 16, 2021, at 8:00 a.m. ET
CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-
Moving Average Crossover Alert: Mersana Therapeutics (MRSN)
07:13am, Friday, 12'th Mar 2021
Mersana Therapeutics (MRSN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Mersana Therapeutics to Present Three Posters at Upcoming Virtual 2021 American Association for Cancer Research Annual Meeting
04:35pm, Wednesday, 10'th Mar 2021
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Mersana Therapeutics, Inc.'s (MRSN) CEO Anna Protopapas on Q4 2020 Results - Earnings Call Transcript
01:33pm, Friday, 26'th Feb 2021
Mersana Therapeutics, Inc.'s (MRSN) CEO Anna Protopapas on Q4 2020 Results - Earnings Call Transcript
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates
08:21am, Friday, 26'th Feb 2021
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -27.27% and -97.65%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for t
Mersana Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
06:00am, Friday, 26'th Feb 2021
- UPLIFT, a single-arm registration strategy evaluating upifitamab rilsodotin (UpRi) in platinum-resistant ovarian cancer, on track to begin in Q1 2021
Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2020 Financial Results and Business Updates
08:00am, Friday, 19'th Feb 2021
CAMBRIDGE, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 22'nd Jan 2021
CAMBRIDGE, Mass., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Carla Poulson Joins Mersana Therapeutics as Chief Human Resources Officer
08:00am, Tuesday, 19'th Jan 2021
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Notable Insider Buys Of The Past Week: Conagra Brands Plus Plenty Of Biotech Activity
02:22pm, Saturday, 16'th Jan 2021
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying c
Mersana: XMT-1536's Complications, New CMO, And 2H 2021's Critical Catalyst
10:52pm, Sunday, 10'th Jan 2021
Mersana Therapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates ("ADCs") for cancer patients. Mersana has developed an early-stage pipeline of 8 therapeutic prog
